GNMK has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
GNMK has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
In calculating the Net Current Asset Value (NCAV), Benjamin Graham means a company's current assets (such as cash, marketable securities, and inventories) minus its total liabilities (including preferred stock, minority interest, and long-term debt).
GenMark Diagnostics's net current asset value per share for the quarter that ended in Dec. 2020 was $0.61.
The historical rank and industry rank for GenMark Diagnostics's Net Current Asset Value or its related term are showing as below:
During the past 13 years, the highest Price-to-Net-Current-Asset-Value Ratio of GenMark Diagnostics was 39.41. The lowest was 23.88. And the median was 27.63.
The historical data trend for GenMark Diagnostics's Net Current Asset Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
GenMark Diagnostics Annual Data | |||||||||||||||||||||
Trend | Dec11 | Dec12 | Dec13 | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | |||||||||||
Net Current Asset Value | Get a 7-Day Free Trial | 0.35 | 0.81 | 0.16 | -0.26 | 0.61 |
GenMark Diagnostics Quarterly Data | ||||||||||||||||||||
Mar16 | Jun16 | Sep16 | Dec16 | Mar17 | Jun17 | Sep17 | Dec17 | Mar18 | Jun18 | Sep18 | Dec18 | Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | |
Net Current Asset Value | Get a 7-Day Free Trial | -0.26 | -0.23 | 0.89 | 0.78 | 0.61 |
For the Medical Devices subindustry, GenMark Diagnostics's Price-to-Net-Current-Asset-Value, along with its competitors' market caps and Price-to-Net-Current-Asset-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Medical Devices & Instruments industry and Healthcare sector, GenMark Diagnostics's Price-to-Net-Current-Asset-Value distribution charts can be found below:
* The bar in red indicates where GenMark Diagnostics's Price-to-Net-Current-Asset-Value falls into.
GenMark Diagnostics's Net Current Asset Value (NCAV) per share for the fiscal year that ended in Dec. 2020 is calculated as
Net Current Asset Value Per Share | (A: Dec. 2020 ) | ||||||||
= | (Total Current Assets | - | Total Liabilities | - | Minority Interest | - | Preferred Stock) | / | Shares Outstanding (EOP) |
= | (172.962 | - | 129.336 | - | 0 | - | 0) | / | 71.96 |
= | 0.61 |
GenMark Diagnostics's Net Current Asset Value (NCAV) per share for the quarter that ended in Dec. 2020 is calculated as
Net Current Asset Value Per Share | (Q: Dec. 2020 ) | ||||||||
= | (Total Current Assets | - | Total Liabilities | - | Minority Interest | - | Preferred Stock) | / | Shares Outstanding (EOP) |
= | (172.962 | - | 129.336 | - | 0 | - | 0) | / | 71.96 |
= | 0.61 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
GenMark Diagnostics (NAS:GNMK) Net Current Asset Value Explanation
Benjamin Graham first discussed net current asset value (NCAV) in the 1934 edition of "Security Analysis", which he coauthored with David Dodd. In the book, (net) current asset value is defined as:" current assets alone, minus all liabilities and claims ahead of the issue."
The common definition of NCAV is: NCAV = current assets – [total liabilities + minority interest + preferred stock]
Net current assets exclude not only the intangible assets but also the fixed and miscellaneous assets. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.
One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Grahams strategy produced similar results.
Benjamin Graham looked for companies whose market values were less than two-thirds of their Net-Net Working Capital. They are collected under our Net-Net screener.
Thank you for viewing the detailed overview of GenMark Diagnostics's Net Current Asset Value provided by GuruFocus.com. Please click on the following links to see related term pages.
Tyler Jensen | officer: SVP, Engineering and Tech Dev | 5964 LA PLACE COURT CARLSBAD CA 92008 |
Christine Shaw | officer: VP, Assay Development | 5964 LA PLACE COURT CARLSBAD CA 92008 |
Alan Baer Maderazo | officer: VP, Qual, Reg, & Clin Affairs | 5964 LA PLACE COURT CARLSBAD CA 92008 |
Michael Gleeson | officer: SVP, Corp. Accounts | 5964 LA PLACE COURT, SUITE 100 CARLSBAD CA 92008 |
Sarah Hollis Winkler | officer: VP, Human Resources | 5964 LA PLACE COURT CARLSBAD CA 92008 |
Michael John Harkins | officer: SVP, Sales | 5964 LA PLACE COURT CARLSBAD CA 92008 |
John Frederick Ek | officer: Chief Financial Officer | 5964 LA PLACE COURT, CARLSBAD CA 92008 |
Scott Mendel | director, officer: President & CEO | 5964 LA PLACE COURT, ADDRESS 2, CARLSBAD CA 92008 |
Eric Stier | officer: SVP & General Counsel | 5964 LA PLACE COURT CARLSBAD CA 92008 |
Brian Andrew Mitchell | officer: SVP, Operations | 5964 LA PLACE COURT CARLSBAD CA 92008 |
Daryl Faulkner | director | 5964 LA PLACE COURT, CARLSBAD CA 92008 |
Michael Kagnoff | director | DLA PIPER LLP (US) 4365 EXECUTIVE DRIVE, SUITE 1100 SAN DIEGO CA 92121 |
Lisa M. Giles | director | DURATA THERAPEUTICS, INC., 200 SOUTH WACKER DRIVE SUITE 2550, CHICAGO IL 60606 |
Kevin C Oboyle | director | 5964 LA PLACE COURT, CARLSBAD CA 92008 |
James Fox | director | 5964 LA PLACE COURT, CARLSBAD CA 92008 |
From GuruFocus
By Marketwired Marketwired • 01-12-2021
By Marketwired Marketwired • 10-15-2020
By GuruFocus Research GuruFocus Editor • 05-03-2021
By GuruFocus Research GuruFocus Editor • 08-18-2020
By GuruFocus Research GuruFocus Editor • 08-14-2020
By Marketwired Marketwired • 12-29-2020
By Marketwired Marketwired • 09-15-2020
By Marketwired Marketwired • 05-12-2020
By Marketwired Marketwired • 02-17-2021
By Marketwired Marketwired • 07-22-2020
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.